© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Barbara Ann Burtness, MD, professor of medicine, Clinical Research Program Leader, Head and Neck Cancers Program and Co-Director, Developmental Therapeutics Research Program at Yale Cancer Center, discusses the ongoing trials looking at immunotherapy as a first-line treatment in head and neck cancer.